Oryzon Genomics S.A.
Stock Details
Is it expensive?
Market Cap
236.09M
Trailing P/E Ratio
-76.18
Forward P/E Ratio
215.43
PEG Ratio
2.74
211.75M
-37.49
Price-to-Sales (TTM)
18.86
1.98
1.52
Is it profitable?
10.87M
Net Profit Margin (TTM)
-20.43%
Gross Profit Margin
0.00%
Diluted EPS (TTM)
-0.03
-2.21%
Is it growing?
0.00%
0.00%
Is it risky?
0.44
0.00
0.00
--
Who owns it?
0.90%
21.27%
0.00%
77.51M
60.52M
Does it pay?
0.00%
0.00%
--
--
How much cash?
0.00
-7.28M
-3.06M
--
- Price (EOD)
- 2.99
- Percent Change
- -0.04 (1.25%)
- Previous Close
- 3.03
- Open
- 3.04
- Low
- 2.97
- High
- 3.10
52-Week Range Position (52WRP)
Below Average
Below Average
within its 1-year price range
€2.99
From 52W Low
+17.18%
From 52W High
-25.52%
Today
-1.25%
1Y Change
+3.24%
6M
€3.20
3M
€2.77
1M
€2.75
Today
€2.99
From 52W Low
+17.18%
From 52W High
-25.52%
Today
-1.25%
1Y Change
+3.24%
6M
€3.20
3M
€2.77
1M
€2.75
Today
€2.99
Below Average
within its 1-year price range
€2.99
Multi-Timeframe Analysis (MTA)
Uptrend
Most timeframes point up. One conflicting period introduces some uncertainty, but the overall direction is positive. Weaker than a Strong Uptrend, but still a bullish signal. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+8.7%
3M
+8.1%
6M
-6.4%
1Y
+3.2%
Rate of Change (ROC)
Accelerating
Price is rising 14.5x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Average
Volume is in line with the 90-day average. No unusual activity detected. Price moves on average volume carry less confirmation. As reflected in the Relative Volume (RVOL) below.
- Name
- Oryzon Genomics S.A.
- Founded
- 2000
- CEO
- Carlos Manuel Buesa Arjol
- Employees
- 46
- Fiscal Year End
- Dec 31, 2025
- Address
Sant Ferran 74
Cornellà de Llobregat
MI
08940
Spain
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.oryzon.com/en
Indicators
Operating Cash Flow
-7.28M
Net Income
-2.22M
Real Earnings
3.28
Cash flow exceeds reported profit. Every dollar of profit is backed by actual cash. Only the most financially disciplined businesses consistently show this pattern.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Related Heatmaps
IBEX Small CapIndex IBEX Small Cap - IBEXSC |
Indicators
Operating Cash Flow
-7.28M
Net Income
-2.22M
Real Earnings
3.28
Cash flow exceeds reported profit. Every dollar of profit is backed by actual cash. Only the most financially disciplined businesses consistently show this pattern.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Stock Details
Is it expensive?
Market Cap
236.09M
Trailing P/E Ratio
-76.18
Forward P/E Ratio
215.43
PEG Ratio
2.74
211.75M
-37.49
Price-to-Sales (TTM)
18.86
1.98
1.52
Is it profitable?
10.87M
Net Profit Margin (TTM)
-20.43%
Gross Profit Margin
0.00%
Diluted EPS (TTM)
-0.03
-2.21%
Is it growing?
0.00%
0.00%
Is it risky?
0.44
0.00
0.00
--
Who owns it?
0.90%
21.27%
0.00%
77.51M
60.52M
Does it pay?
0.00%
0.00%
--
--
How much cash?
0.00
-7.28M
-3.06M
--
- Price (EOD)
- 2.99
- Percent Change
- -0.04 (1.25%)
- Previous Close
- 3.03
- Open
- 3.04
- Low
- 2.97
- High
- 3.10
52-Week Range Position (52WRP)
Below Average
Below Average
within its 1-year price range
€2.99
From 52W Low
+17.18%
From 52W High
-25.52%
Today
-1.25%
1Y Change
+3.24%
6M
€3.20
3M
€2.77
1M
€2.75
Today
€2.99
From 52W Low
+17.18%
From 52W High
-25.52%
Today
-1.25%
1Y Change
+3.24%
6M
€3.20
3M
€2.77
1M
€2.75
Today
€2.99
Below Average
within its 1-year price range
€2.99
Multi-Timeframe Analysis (MTA)
Uptrend
Most timeframes point up. One conflicting period introduces some uncertainty, but the overall direction is positive. Weaker than a Strong Uptrend, but still a bullish signal. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+8.7%
3M
+8.1%
6M
-6.4%
1Y
+3.2%
Rate of Change (ROC)
Accelerating
Price is rising 14.5x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Average
Volume is in line with the 90-day average. No unusual activity detected. Price moves on average volume carry less confirmation. As reflected in the Relative Volume (RVOL) below.
- Name
- Oryzon Genomics S.A.
- Founded
- 2000
- CEO
- Carlos Manuel Buesa Arjol
- Employees
- 46
- Fiscal Year End
- Dec 31, 2025
- Address
Sant Ferran 74
Cornellà de Llobregat
MI
08940
Spain
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.oryzon.com/en
Related Heatmaps
IBEX Small CapIndex IBEX Small Cap - IBEXSC |